Autoantibody to vasoactive intestinal peptide in human circulation
- PMID: 3839670
- DOI: 10.1016/0006-291x(85)90442-5
Autoantibody to vasoactive intestinal peptide in human circulation
Abstract
In a radioassay for Vasoactive Intestinal Peptide (VIP)-binding, eight out of 33 plasma samples from healthy human subjects exhibited specific binding ranging from 2.6% to 46.7% of total [125 I]VIP. This binding was competitively displaced by unlabeled VIP. The structurally homologous peptides, Peptide Histidine Isoleucine (PHI) and secretin, were, respectively, 72-fold and 413-fold less potent than VIP in displacing bound [125 I]VIP, whereas the unrelated peptides, neurotensin, eledoisin, bombesin and metenkephalin, were without effect on the binding. The antibody nature of the VIP-binding factor was suggested by its precipitation with ammonium sulfate, attenuation after absorption with Staphylococcus aureus preparations, precipitation with antisera against human IgG and IgM, and coelution with standard IgG and IgM on anion-exchange and high-performance gel-filtration columns. Pepsin treatment of purified IgG fraction yielded a VIP-binding species with apparent molecular weight of 108 +/- 13 kDa that was precipitated by antiserum against the F(ab)2 fragment of the IgG molecule. These results demonstrate the existence in some human plasmas of an autoantibody that binds VIP.
Similar articles
-
Characterization of autoantibodies to vasoactive intestinal peptide in asthma.J Neuroimmunol. 1989 Jul;23(2):133-42. doi: 10.1016/0165-5728(89)90032-5. J Neuroimmunol. 1989. PMID: 2542371
-
Molecular forms of peptide histidine isoleucine-like immunoreactivity in the gastrointestinal tract. Nonequimolar levels of peptide histidine isoleucine and vasoactive intestinal peptide in the stomach explained by the presence of a big peptide histidine isoleucine-like molecule.Gastroenterology. 1985 Sep;89(3):516-24. doi: 10.1016/0016-5085(85)90445-7. Gastroenterology. 1985. PMID: 3839480
-
Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody.Science. 1989 Jun 9;244(4909):1158-62. doi: 10.1126/science.2727702. Science. 1989. PMID: 2727702
-
Binding and multiple hydrolytic sites in epitopes recognized by catalytic anti-peptide antibodies.Ciba Found Symp. 1991;159:156-67; discussion 167-73. doi: 10.1002/9780470514108.ch11. Ciba Found Symp. 1991. PMID: 1720373 Review.
-
Immunobiology of vasoactive intestinal peptide (VIP).Immunol Today. 2000 Jan;21(1):7-11. doi: 10.1016/s0167-5699(99)01525-x. Immunol Today. 2000. PMID: 10637552 Review. No abstract available.
Cited by
-
VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway.Lung. 1994;172(3):159-67. doi: 10.1007/BF00175944. Lung. 1994. PMID: 8201830
-
Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy.PLoS One. 2011;6(11):e28304. doi: 10.1371/journal.pone.0028304. Epub 2011 Nov 30. PLoS One. 2011. PMID: 22140573 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources